Generated by AI
Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery. Pulmonx also provides the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which support patient evaluation, treatment planning, and clinical decision-making. Its products are used primarily by hospitals and specialty pulmonary centers within interventional pulmonology. Pulmonx serves a global clinical market and positions its portfolio around evidence-based tools that help physicians identify appropriate patients and deliver targeted lung-volume reduction therapy.
Website700 Chesapeake Drive
Redwood City, CA, 94063
United States
The latest articles about LUNG.
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumFormat: Fireside chat and 1x1 meetingsDate: Wednesday, November 11Fireside Chat Time: 9:30 AM – 9:55 AM ET Stifel 2026 Healthcare ConferenceFormat: Fire
Summary of Oct 29's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about LUNG also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.